Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Plasmodium vivax exhibits dormant liver-stage parasites, called hypnozoites, which can cause relapse of malaria. The only drug currently used for eliminating hypnozoites is primaquine. The antimalarial properties of primaquine are dependent on the production of oxidized metabolites by the cytochrome P450 isoenzyme 2D6 (CYP2D6). Reduced primaquine metabolism may be related to P. vivax relapses. We describe a case of 4 episodes of recurrence of vivax malaria in a patient with decreased CYP2D6 function. The patient was 52-year-old male with body weight of 52 kg. He received total gastrectomy and splenectomy 7 months before the first episode and was under chemotherapy for the gastric cancer. The first episode occurred in March 2019 and each episode had intervals of 34, 41, and 97 days, respectively. At the first and second episodes, primaquine was administered as 15 mg for 14 days. The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes. Seven gene sequences of P. vivax were analyzed and revealed totally identical for all the 4 samples. The CYP2D6 genotype was analyzed and intermediate metabolizer phenotype with decreased function was identified.
Abstract
Plasmodium vivax exhibits dormant liver-stage parasites, called hypnozoites, which can cause relapse of malaria. The only drug currently used for eliminating hypnozoites is primaquine. The antimalarial properties of primaquine are dependent on the production of oxidized metabolites by the cytochrome P450 isoenzyme 2D6 (CYP2D6). Reduced primaquine metabolism may be related to P. vivax relapses. We describe a case of 4 episodes of recurrence of vivax malaria in a patient with decreased CYP2D6 function. The patient was 52-year-old male with body weight of 52 kg. He received total gastrectomy and splenectomy 7 months before the first episode and was under chemotherapy for the gastric cancer. The first episode occurred in March 2019 and each episode had intervals of 34, 41, and 97 days, respectively. At the first and second episodes, primaquine was administered as 15 mg for 14 days. The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes. Seven gene sequences of P. vivax were analyzed and revealed totally identical for all the 4 samples. The CYP2D6 genotype was analyzed and intermediate metabolizer phenotype with decreased function was identified.
참고문헌 (17)
- Chai Jong-Yil, "History and Current Status of Malaria in Korea", Infection and Chemotherapy, 52(3), pp.441~452 (2020), 대한감염학회[DOI]
- Brittney M. J. Potter, "Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics", Antimicrobial Agents and Chemotherapy, 59(4), pp.2380~2387 (2015), American Society for Microbiology[DOI]
- Sean R. Marcsisin, "Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art", Pharmacology & Therapeutics, 161, pp.1~10 (2016), Elsevier BV[DOI]
- Jason W. Bennett, "Primaquine Failure and Cytochrome P-450 2D6 in <i>Plasmodium vivax<", i> Malaria, 2013, pp.369(14), 1381~1382[DOI]
- J. Kevin Baird, "Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent<i>Plasmodium vivax<", i>Malaria, 2018, pp.1(4), e181449~[DOI]
- Youn-Kyoung Goo, "First Evaluation of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in Vivax Malaria Endemic Regions in the Republic of Korea", PLoS ONE, 9(5), pp.e97390~ (2014), Public Library of Science (PLoS)[DOI]
- Jae Hyoung Im, "Malaria control and chemoprophylaxis policy in the Republic of Korea Armed Forces for the previous 20 years (1997–2016)", Malaria Journal, 17(1), pp.1~9 (2018), Springer Science and Business Media LLC[DOI]
- Mallika Imwong, "Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1", Malaria Journal, 4(1), pp.20~ (2005), Springer Science and Business Media LLC[DOI]
- Kelly E. Caudle, "Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group", Clinical and Translational Science, 13(1), pp.116~124 (2019), Wiley[DOI]
- Flávia Carolina F. de Araujo, "Multiple-Clone Activation of Hypnozoites Is the Leading Cause of Relapse in Plasmodium vivax Infection", PLoS ONE, 7(11), pp.e49871~ (2012), Public Library of Science (PLoS)[DOI]
- Mallika Imwong, "Relapses of<i>Plasmodium vivax<", i>Infection Usually Result from Activation of Heterologous Hypnozoites, 2007, pp.195(7), 927~933[DOI]
- L. H. Schmidt, "Radical Cure of Infections with Plasmodium cynomolgi: a Function of Total 8-Aminoquinoline Dose *", The American Journal of Tropical Medicine and Hygiene, 26(6), pp.1116~1128 (1977), American Society of Tropical Medicine and Hygiene[DOI]
- Noor Hafizan Mat Salleh, "Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia", Transactions of The Royal Society of Tropical Medicine and Hygiene, 114(9), pp.700~703 (2020), Oxford University Press (OUP)[DOI]
- Alexandra Martin Ramírez, "Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function", Malaria Journal, 19(1), pp.259~ (2020), Springer Science and Business Media LLC[DOI]
- "Clinical drug interaction studies—Cytochrome P450 enzyme-and transporter-mediated drug interactions guidance for industry" (2020)[URL]
- Tagariello G, "Dramatic post-splenectomy onset of malaria caused by latent Plasmodium vivax in a female immigrant with severe immunological anaemia", Blood Transfus, 12, pp.428~430 (2014)[DOI]
- Steven Kho, "High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia", Clinical Infectious Diseases, 68(1), pp.51~60 (2018), Oxford University Press (OUP)[DOI]